74 completed. 74 Phase 2, 8 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 74 | Completed 74 |
| Phase 3 | 8 | Completed 8 |
| Phase 1 | 5 | Completed 5 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) EVO756, Placebo control - Chronic Spontaneous Urticaria | Phase 2 | Completed | Evommune, Inc. | 182 | 2025-03-20 | 2026-07-01 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria Oral EVO756 300 mg QD, Oral EVO756 50 mg BID - Chronic Inducible Urticaria | Phase 2 | Completed | Evommune, Inc. | 30 | 2024-08-14 | 2026-05-19 |
| Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment LP-003, Placebo, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Longbio Pharma | 202 | 2024-01-26 | 2026-10-21 |
| Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Briquilimab, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Completed | Jasper Therapeutics, Inc. | 87 | 2023-11-29 | 2026-08-06 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | Incyte Corporation | 136 | 2023-07-31 | 2026-03-12 |
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome VTX2735 - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zomagen Biosciences Ltd. | 7 | 2023-03-18 | 2025-03-10 |
| A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema Navenibart - Hereditary Angioedema | Phase 1 / Phase 2 | Completed | Astria Therapeutics, Inc. | 29 | 2023-02-21 | 2026-05-08 |
| Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares ARS-1 - Urticaria | Phase 2 | Completed | ARS Pharmaceuticals, Inc. | 21 | 2022-07-28 | 2026-04-07 |
| A Study of CDX-0159 in Patients With Chronic Inducible Urticaria barzolvolimab, Matching Placebo - Chronic Inducible Urticaria | Phase 2 | Completed | Celldex Therapeutics | 196 | 2022-06-28 | 2025-11-06 |
| A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria TAS5315 Dose 1, TAS5315 Dose 2, TAS5315 Dose 3 - Chronic Spontaneous Urticaria | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 126 | 2022-06-28 | 2024-08-07 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) ZYIL1 capsule - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zydus Lifesciences Limited | 3 | 2022-06-01 | 2022-07-11 |
| A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria barzolvolimab, Matching Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Celldex Therapeutics | 208 | 2022-05-19 | 2025-03-26 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine rilzabrutinib, placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Sanofi | 160 | 2021-11-24 | 2026-08-06 |
| Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) DFV890 - Familial Cold Autoinflammatory Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 4 | 2021-09-20 | 2024-10-09 |
| Modified Xiao-Feng Powder for Chronic Urticaria Modified Xiao-Feng Powder + Antiallergics, Placebo + Antiallergics - Chronic Urticaria | Phase 2 | Completed | Prof. Lin Zhixiu | 58 | 2021-08-15 | 2026-07-27 |
| Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Amgen | 183 | 2021-04-15 | 2025-04-09 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
| An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema Donidalorsen - Hereditary Angioedema | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 20 | 2020-03-31 | 2026-05-08 |
| Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients CBD - Chronic Spontaneous Urticaria | Phase 2 | Completed | Stero Biotechs Ltd. | 15 | 2020-02-01 | 2024-04-18 |
| A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema Donidalorsen, Placebo - Hereditary Angioedema | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 23 | 2020-01-07 | 2023-04-03 |
Showing 20 of 74. Sign in to see all of them.
Chronic Urticaria (25) · Angioedemas, Hereditary (21) · Angioedema (9) · Pruritus (7) · Cryopyrin-Associated Periodic Syndromes (6) · Cold Urticaria (4) · Hereditary Angioedema Types I and II (4) · Urticaria, Solar (3) · Bronchiolitis Obliterans Syndrome (2) · Chronic Inducible Urticaria (2) · Hypersensitivity (2) · Acquired angioedema (1) · Anaphylaxis (1) · Bronchial Spasm (1)
Hypersensitivity, Immediate (74) · Skin and Connective Tissue Diseases (74) · Immune System Diseases (73) · Skin Diseases (73) · Skin Diseases, Vascular (73) · Hypersensitivity (72) · Pathological Conditions, Signs and Symptoms (38) · Disease Attributes (36) · Chronic Disease (35) · Pathologic Processes (35) · Cardiovascular Diseases (29) · Vascular Diseases (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (27) · Genetic Diseases, Inborn (26)
Omalizumab (12) · Complement C1 Inhibitor Protein (7) · SERPING1 protein, human (4) · conestat alfa (4) · berotralstat (3) · ligelizumab (3) · rilonacept (3) · IONIS-PKK-LRx (2) · Sodium Chloride (2) · avoralstat (2) · bilastine (2) · canakinumab (2) · donidalorsen (2) · dupilumab (2) · AK002 (1)
Charite University, Berlin, Germany (8) · Novartis Pharmaceuticals (8) · BioCryst Pharmaceuticals (5) · Shire (5) · Genentech, Inc. (4) · Pharming Technologies B.V. (4) · CSL Behring (3) · Johns Hopkins University (3) · Celldex Therapeutics (2) · Centre Hospitalier Universitaire de Besancon (2) · Evommune, Inc. (2) · Ionis Pharmaceuticals, Inc. (2) · Prothya Biosolutions (2) · ARS Pharmaceuticals, Inc. (1) · Allakos Inc. (1)
Germany (40) · United States (38) · Canada (17) · Spain (16) · United Kingdom (15) · Hungary (14) · Poland (13) · France (11) · Italy (10) · Netherlands (10) · Australia (8) · Czechia (8) · Japan (8) · Israel (7) · North Macedonia (7)
Marcus Maurer, MD (4) · Anurag Relan, MD (2) · Karoline Krause, MD (2) · M. M. Levi, Prof. Dr. (2) · Marcus Maurer, Prof. (2) · Baek-Hwan Cho, MD., PhD (1) · Bruno Giannetti, MD (1) · Clifton O. Bingham, M.D. (1) · Dr Deven Parmar, MD (1)
PMID 36326435, PMID 36408587, PMID 34773261, PMID 36440464, PMID 18668591, PMID 19767078, PMID 20674826, PMID 20920772, PMID 21356079, PMID 21762974, PMID 22136279, PMID 22583335, PMID 23535096, PMID 23878046, PMID 23987198, PMID 24712435, PMID 25629740, PMID 26016741, PMID 26171584, PMID 27931305, PMID 28284978, PMID 28389393, PMID 28754491, PMID 29974963, PMID 30044938, PMID 30993784, PMID 31577874, PMID 34161665, PMID 35219377, PMID 35294812, PMID 35820771, PMID 35869554, PMID 36774155, PMID 36973954, PMID 37492920, PMID 37866460, PMID 38006972, PMID 38009241, PMID 38020288, PMID 38710185, PMID 40266575, PMID 40490218, PMID 41747871, PMID 41794053, PMID 41802598, PMID 41865747, PMID 42159953, PMID 42268494, PMID 42318595
2017 (3), 2018 (2), 2019 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2023 (1)